



THERMOGENESIS' CRYOSEAL® FIBRIN SEALANT SYSTEM AND THROMBIN PROCESSING DEVICE™ (TPD™) TO BE DISTRIBUTED IN SWITZERLAND AND IRELAND

RANCHO CORDOVA, California (August 29, 2005) -- THERMOGENESIS CORP. (Nasdaq: KOOL) announced today that the Company signed distribution agreements for both the CryoSeal and TPD products with two European surgical device distributors.

- **Affinity Supplies, LLC** is a Dublin-based company whose main customers are Irish Healthcare Institutions, both public and private. The company's core strengths are in the sales and marketing of disposable products and instrumentation relevant to these markets. Affinity Supplies will focus on the use of CryoSeal and TPD in orthopedic, cardiac, urology, vascular and general surgery. The company has good relationships with both the blood bank and the surgical community.
- **BitMedical GmbH** (Blood Interventional Technologies), Switzerland provides equipment and disposables for cell washing plasma pheresis, platelet pheresis, platelet gel and heparin management for anesthesiologists, surgeons and blood banks. BitMedical is the market leader in Switzerland in point of care management of autologous blood products and maintains fully qualified 24-hour technical support for all their products.

According to Rudy Huylebroeck, ThermoGenesis' Director of Global Sales & Marketing in Hospital/Wound Care, Affinity Supplies and BitMedical join an expanding list of CryoSeal and TPD distributors in Europe. Other distributors are in place in Italy, Russia, Turkey, Sweden, and the Netherlands. ThermoGenesis expects distribution for these products in a majority of European countries before the end of calendar year 2005.

Regulatory Status

ThermoGenesis Corp. has received a right to affix the CE Mark to the CryoSeal FS System from its European Notified Body. In Japan, Asahi Kasei Medical, who is the Japanese distributor, has completed their PMA submission to the MHLW. A 150-patient, blinded multi-center Phase III clinical trial of CryoSeal FS System has completed enrollment in the United States and a PMA submission is being prepared.

The TPD manufactured by ThermoGenesis has received CE Mark approval from the European Union Competent Authorities. The regulatory pathway in the United States will require a Pre-Market Approval Application for the platelet gel product of which autologous thrombin is a component.

About ThermoGenesis Corp.

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

More Information, Contact:
THERMOGENESIS CORP.
Rudy Huylebroeck: (916) 858-5100